Previous 10 |
Initial public offerings offer public market investors the earliest chance to own a piece of a promising company. Capital-intensive fields like drug development have continued to witness a stream of IPOs -- some more successful than others. Besides raising cash for company operations, a public ...
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present ...
The following slide deck was published by Frequency Therapeutics, Inc. in conjunction with this Read more ...
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present...
Gainers: Amneal Pharmaceuticals (NYSE: AMRX ) +49% . More news on: Amneal Pharmaceuticals, Inc., Diebold Nixdorf, Incorporated, Assembly Biosciences, Inc., Stocks on the move, Read more ...
Gainers: AMRS +11.7% . GGB +4.9% . EVBG +4.3% . FREQ +2.8% . ACC +1.9% . More news on: Amyris, Inc., Gerdau S.A., Everbridge, Inc., Stocks on the move, , News on ETFs Read more ...
News, Short Squeeze, Breakout and More Instantly...
Frequency Therapeutics Inc. Company Name:
FREQ Stock Symbol:
NYSE Market:
Frequency Therapeutics, Inc. (Nasdaq: FREQ) today announced business updates and financial results for the second quarter ended June 30, 2023. In July, the Company announced that it entered into a definitive merger agreement with Korro Bio, Inc., a leading RNA editing company focused on the d...
2023-07-15 06:36:00 ET 3 Things to Know About Using Analyst Opinions for Trading Penny Stocks Trading penny stocks can be a thrilling venture, offering the potential for significant returns on small investments. One of the key aspects that can influence the success of such trades is the...
Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio’s wholly owned portfolio of RNA editing programs Lead program is a disease modifying therapy for patients with alpha-1 antitrypsin deficiency (AATD), with preclinical data showing an increase ...